

Development of a combination therapy for colorectal cancer using attenuated Salmonella and anti-PD-L1 antibody

ONCOLOGY	Candidate
Product Type	Biopharmaceuticals
Indication	Colorectal cancer (late stage)
Target	Colorectal cancer (late stage) patients
MoA(Mechanism of Action)	<ul style="list-style-type: none"> ① Attenuated Salmonella typhimurium ② Tumor targeting function based on bacteria motility and chemotaxis ③ Pro-inflammatory anticancer immune response ④ Increased anticancer efficacy by anti-PD-L1 antibody combination
Competitiveness	<ul style="list-style-type: none"> ① Higher colonization effect compared to existing clinical trial salmonella ② Minimized side effects by attenuated bacteria ③ Increased immune response activity by combination therapy with anti-PD-L1 ④ Induced long-term anticancer immune memory response
Development Stage	Candidate
Route of Administration	Intravenous injection